SOUTH SAN FRANCISCO, Calif.,
Feb. 5, 2020 /PRNewswire/
-- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug
discovery, development and manufacturing company focused on the
application of precise protein engineering and rational design to
create next-generation oncology therapeutics, today announced the
expansion of its senior management team with the appointments of
Kristin Bedard, Ph.D., as Vice
President of Immunobiology, and Brunilda
Shtylla as Vice President of Business Development.
"Kristin brings a proven track record of advancing novel
therapies into the clinic, with expertise in immuno-oncology and
demonstrated scientific leadership. Brunilda has deep experience in
the biopharma industry and brings strategic evaluation, analysis
and negotiation skills to Sutro to support business development
opportunities," said Bill Newell,
Sutro's Chief Executive Officer. "These appointments provide an
expanded breadth of key scientific and business expertise to drive
the ongoing advancement of our clinical pipeline and partnerships
utilizing our technology."
Dr. Bedard previously held leadership positions at Kineta, most
recently as Chief Scientific Officer, Immuno-oncology and Senior
Vice President, Discovery and formerly as Vice President of R&D
and Head of Virology. She is the co-inventor of fifteen filed U.S.
patent applications for novel classes of antivirals, adjuvants,
immune agonists and their corresponding methods of identification.
Dr. Bedard received her B.S. from Pennsylvania
State University and earned her Ph.D. from University of California, Irvine.
Ms. Shtylla worked as an independent consultant since 2012,
which included consulting for Genentech since 2013. Prior to this,
she held numerous positions at Lifescan, a Johnson & Johnson
company, including Associate Director of Partnerships and Product
Director, U.S. Brand Marketing. Previously, Ms. Shtylla held roles
in Business Development, Technology Transfer, Sales &
Operations Planning, Investment Banking and Finance. She received
her B.S. from Wayne State University, a
M.S. in Mathematics from Youngstown State
University and an M.B.A. from Stanford Graduate School of
Business.
About Sutro Biopharma
Sutro Biopharma, Inc., located
in South San Francisco, is a
clinical-stage drug discovery, development and manufacturing
company. Using precise protein engineering and rational design,
Sutro is advancing next-generation oncology therapeutics.
Sutro's proprietary and integrated cell-free protein synthesis
and site-specific conjugation platform, XpressCF™, led to the
discovery of Sutro's first two internally-developed ADCs. One of
these proprietary drug candidates is a folate receptor alpha
(FolRα)-targeting ADC, currently being investigated in a Phase I
clinical trial of patients with ovarian and endometrial cancers
(STRO-002). Sutro's other proprietary drug candidate, (STRO-001) is
a CD74-targeting ADC currently being investigated in a Phase I
clinical trial of patients with advanced B-cell malignancies,
including multiple myeloma and non-Hodgkin lymphoma. STRO-001 was
granted Orphan Drug Designation by the FDA for multiple myeloma in
October 2018. A third program,
CC-99712 (BCMA-targeting ADC), which is part of Sutro's
collaboration with Bristol-Myers Squibb (formerly Celgene
Corporation), is enrolling patients for its Phase I clinical trial
of patients with multiple myeloma. Sutro's proprietary technology
was responsible for the discovery and manufacturing of CC-99712,
for which Bristol-Myers Squibb has worldwide development and
commercialization rights. Sutro is entitled to development and
regulatory milestone payments and tiered royalties from
Bristol-Myers Squibb for this BCMA ADC.
Sutro is dedicated to transforming the lives of cancer patients
by creating medicines with improved therapeutic profiles for areas
of unmet need.
To date, Sutro has designed cytokine-based immuno-oncology
therapies, ADCs, vaccines and bispecific antibodies primarily
directed at clinically-validated targets for which the current
standard of care is suboptimal.
Sutro's platform allows it to accelerate discovery and
development of potential first-in-class and best-in-class molecules
through rapid and systematic evaluation of protein
structure-activity relationships to create optimized homogeneous
product candidates.
In addition to developing its own oncology pipeline, Sutro is
collaborating with select pharmaceutical and biotech companies to
discover and develop novel, next-generation therapeutics. As the
pace of clinical development accelerates, Sutro and its partners
are developing therapeutics designed to more efficiently kill
tumors without harming healthy cells.
Additional multimedia content from Sutro regarding STRO-001 and
STRO-002 can be found here and here.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to
learn more about our passion for changing the future of
oncology.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated preclinical and clinical development
activities, potential benefits of the company's product candidates
and platform and potential market opportunities for the company's
product candidates. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. Although the company believes that the expectations
reflected in such forward-looking statements are reasonable, the
company cannot guarantee future events, results, actions, levels of
activity, performance or achievements, and the timing and results
of biotechnology development and potential regulatory approval is
inherently uncertain. Forward-looking statements are subject to
risks and uncertainties that may cause the company's actual
activities or results to differ significantly from those expressed
in any forward-looking statement, including risks and uncertainties
related to the company's ability to advance its product candidates,
the receipt and timing of potential regulatory designations,
approvals and commercialization of product candidates, the
Company's ability to maintain and recognize the benefits of certain
designations received by product candidates, the timing and results
of preclinical and clinical trials, the company's ability to fund
development activities and achieve development goals, the company's
ability to protect intellectual property, and the Company's
commercial collaborations with third parties and other risks and
uncertainties described under the heading "Risk Factors" in
documents the company files from time to time with the Securities
and Exchange Commission. These forward-looking statements speak
only as of the date of this press release, and the company
undertakes no obligation to revise or update any forward-looking
statements to reflect events or circumstances after the date
hereof.
Investor Contacts
John Graziano
Solebury Trout
+1 646-378-2942
jgraziano@soleburytrout.com
Xuan Yang
Solebury Trout
+1 646-378-2975
xyang@soleburytrout.com
Media Contacts
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Travis Kruse
Russo Partners
(212) 845-4272
travis.kruse@russopartnersllc.com
View original
content:http://www.prnewswire.com/news-releases/sutro-biopharma-expands-senior-management-team-with-the-appointments-of-vice-president-of-immunobiology-and-vice-president-of-business-development-300998571.html
SOURCE Sutro Biopharma